ExploreWatchlistsPricing
  1. JP-listed companies
  2. COSMO BIO COMPANY, LIMITED
  3. Financials
  4. Cash and cash equivalents

COSMO BIO COMPANY, LIMITED (3386)

Market cap
¥7.6B
P/E ratio
32.6x
Cosmo Bio imports and sells life science research reagents and equipment to researchers at universities and corporations, offering over 10 million products from 500 companies worldwide.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndCash and cash equivalents (Million JPY)YoY (%)
Dec 31, 20252,747+14.79%
Dec 31, 20242,393-15.32%
Dec 31, 20232,826-6.92%
Dec 31, 20223,036-6.73%
Dec 31, 20213,255+3.04%
Dec 31, 20203,159+30.75%
Dec 31, 20192,416+16.83%
Dec 31, 20182,068+49.53%
Dec 31, 20171,383-16.08%
Dec 31, 20161,648+50.09%
Dec 31, 20151,098+11.93%
Dec 31, 2014981

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat